<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00847704</url>
  </required_header>
  <id_info>
    <org_study_id>IRB 4005</org_study_id>
    <nct_id>NCT00847704</nct_id>
  </id_info>
  <brief_title>Clinic-Based AMES Treatment of Stroke</brief_title>
  <official_title>Clinic-Based Ames Treatment of the Lower Extremity in Chronic Stroke Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oregon Health and Science University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>AMES Technology</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Oregon Health and Science University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study investigates whether assisted movement with biofeedback and muscle vibration
      applied to the lower limb reduces impairment and improves gait.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The hypothesis of this study is that chronic stroke survivors, more than one year
      post-stroke, with a motor problems in the lower extremity will be able to walk and move the
      affected leg better after 30 treatments with a new robotic therapy device, the AMES device.
      The device rotates the ankle while vibrators stimulate the tendons attached to muscles that
      move the ankle. Testing will be done before, during and after the treatments to determine
      response to the therapy.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Funding not available.
  </why_stopped>
  <start_date>April 2008</start_date>
  <completion_date type="Actual">November 2009</completion_date>
  <primary_completion_date type="Actual">November 2009</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fugl-Meyer Assessment of the Lower Extremity</measure>
    <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
    <description>Gold standard for motor impairment in individuals with stroke. A scale measuring tone, range-of-motion and synergies of the lower limb with a range of 0-34, higher scores referring to improved motor ability. The assessment includes 7 subscales, the scores of which are summed to arrive at a total score.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Timed 10-Meter Walk</measure>
    <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
    <description>Gait Assessment - Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Stroke Impact Scale</measure>
    <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
    <description>The Stroke Impact Scale is a self-assessment questionnaire concerning activities of daily living. There are 8 sub-scales, each of which is summed as a raw score (range of 0-100) and then transformed as follows:
Transformed Scale=[(Actual raw score-lowest possible raw score)/Possible raw score range]x100.
Thus, the maximum possible score for the entire measure is 800. A higher score indicates a higher level of functioning.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spasticity (Modified Ashworth) Scale</measure>
    <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
    <description>Measure of the total Ashworth scoring for increased muscle tone in the ankle flexors, ankle extensors, knee flexors, and knee extensors in the affected leg of stroke subjects. The scale range is from 0-5, with higher levels representing more exaggerated tone.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Strength Test</measure>
    <time_frame>First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)</time_frame>
    <description>Measurement of ankle dorsiflexion/plantarflexion isometric strength (change-score from average of first 3 training sessions and last 3 training sessions).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Active Motion Test</measure>
    <time_frame>First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)</time_frame>
    <description>Tracking task. Active joint position control between dorsiflexion/plantarflexion (change-score from average of first 3 training sessions and last 3 training sessions). The score is based on the amount of time that the participant is able to position the joint in a 3 deg-wide target zone presented on a video screen.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">3</enrollment>
  <condition>Stroke</condition>
  <condition>Cerebrovascular Accident</condition>
  <arm_group>
    <arm_group_label>Test treatment group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Device: Assisted movement and enhanced sensation</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Assisted movement and enhanced sensation</intervention_name>
    <description>Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.</description>
    <arm_group_label>Test treatment group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  At least 12 months post-stroke

          -  Cognitively and behaviorally capable of complying with the regimen

          -  Functioning proprioception

          -  Less than 50% of normal strength in the affected ankle, but able to stand with or
             without assistive devices

        Exclusion Criteria:

          -  Fractures of treated limb resulting in loss of range of motion

          -  Spinal cord injury

          -  Deep vein thrombosis

          -  Peripheral nerve injury or neuropathy in the limb affected with motor disability

          -  Osteoarthritis limiting range of motion

          -  Skin condition not tolerant of device

          -  Progressive neurodegenerative disorder

          -  Uncontrolled seizure disorder

          -  Botox treatment within the last 5 months

          -  Baclofen pump
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Paul J. Cordo, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AMES Technology Inc./Oregon Health and Science University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Oregon Health and Science University</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://nnr.sagepub.com/content/23/1.toc</url>
    <description>Neurorehabilitation and Neural Repair Volume 23(1), 2009</description>
  </link>
  <reference>
    <citation>Cordo P, Lutsep H, Cordo L, Wright WG, Cacciatore T, Skoss R. Assisted movement with enhanced sensation (AMES): coupling motor and sensory to remediate motor deficits in chronic stroke patients. Neurorehabil Neural Repair. 2009 Jan;23(1):67-77. doi: 10.1177/1545968308317437. Epub 2008 Jul 21.</citation>
    <PMID>18645190</PMID>
  </reference>
  <verification_date>November 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 18, 2009</study_first_submitted>
  <study_first_submitted_qc>February 18, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 19, 2009</study_first_posted>
  <results_first_submitted>December 17, 2014</results_first_submitted>
  <results_first_submitted_qc>November 23, 2016</results_first_submitted_qc>
  <results_first_posted type="Estimate">January 23, 2017</results_first_posted>
  <last_update_submitted>November 23, 2016</last_update_submitted>
  <last_update_submitted_qc>November 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 23, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Oregon Health and Science University</investigator_affiliation>
    <investigator_full_name>Paul J. Cordo</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Stroke</keyword>
  <keyword>Rehabilitation</keyword>
  <keyword>Robotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Stroke</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Group</title>
          <description>Device: Assisted movement and enhanced sensation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Stroke &gt;1 yr prior to enrollment Able to stand independently &lt;50% normal strength in affected leg Functioning proprioception in affected leg</population>
      <group_list>
        <group group_id="B1">
          <title>Test Group</title>
          <description>Device: Assisted movement and enhanced sensation
Assisted movement and enhanced sensation: Each subject will be tested before, after the 10 week treatment period and then 3 months later. Treatment sessions will occur 3 times per week and last approximately 30 minutes per treatment. The device will measure 3 of the functional tests prior to each treatment session.
Assisted movement and enhanced sensation: Thirty treatment sessions on the AMES device, each session 30 minutes of cyclic rotation of the ankle with tendon vibration. Testing before, during, and after treatments to evaluate response to treatments.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="2"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="67" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Time since stroke</title>
          <units>Months</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113.5" spread="85.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Fugl-Meyer Assessment of the Lower Extremity</title>
        <description>Gold standard for motor impairment in individuals with stroke. A scale measuring tone, range-of-motion and synergies of the lower limb with a range of 0-34, higher scores referring to improved motor ability. The assessment includes 7 subscales, the scores of which are summed to arrive at a total score.</description>
        <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Fugl-Meyer Assessment of the Lower Extremity</title>
          <description>Gold standard for motor impairment in individuals with stroke. A scale measuring tone, range-of-motion and synergies of the lower limb with a range of 0-34, higher scores referring to improved motor ability. The assessment includes 7 subscales, the scores of which are summed to arrive at a total score.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="19.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="21" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Timed 10-Meter Walk</title>
        <description>Gait Assessment - Time</description>
        <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Timed 10-Meter Walk</title>
          <description>Gait Assessment - Time</description>
          <units>seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.465" spread="0.055"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.66" spread="0.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.27" spread="0.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Stroke Impact Scale</title>
        <description>The Stroke Impact Scale is a self-assessment questionnaire concerning activities of daily living. There are 8 sub-scales, each of which is summed as a raw score (range of 0-100) and then transformed as follows:
Transformed Scale=[(Actual raw score-lowest possible raw score)/Possible raw score range]x100.
Thus, the maximum possible score for the entire measure is 800. A higher score indicates a higher level of functioning.</description>
        <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Stroke Impact Scale</title>
          <description>The Stroke Impact Scale is a self-assessment questionnaire concerning activities of daily living. There are 8 sub-scales, each of which is summed as a raw score (range of 0-100) and then transformed as follows:
Transformed Scale=[(Actual raw score-lowest possible raw score)/Possible raw score range]x100.
Thus, the maximum possible score for the entire measure is 800. A higher score indicates a higher level of functioning.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="234.5" spread="9.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="258" spread="4.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="251.5" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spasticity (Modified Ashworth) Scale</title>
        <description>Measure of the total Ashworth scoring for increased muscle tone in the ankle flexors, ankle extensors, knee flexors, and knee extensors in the affected leg of stroke subjects. The scale range is from 0-5, with higher levels representing more exaggerated tone.</description>
        <time_frame>Pre-training, After 30 training sessions (8-10 weeks), 3-Month Follow-up</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Spasticity (Modified Ashworth) Scale</title>
          <description>Measure of the total Ashworth scoring for increased muscle tone in the ankle flexors, ankle extensors, knee flexors, and knee extensors in the affected leg of stroke subjects. The scale range is from 0-5, with higher levels representing more exaggerated tone.</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Baseline</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="2.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Post-treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.5" spread="0.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>3 Month Follow-up</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.0" spread="1.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Strength Test</title>
        <description>Measurement of ankle dorsiflexion/plantarflexion isometric strength (change-score from average of first 3 training sessions and last 3 training sessions).</description>
        <time_frame>First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Strength Test</title>
          <description>Measurement of ankle dorsiflexion/plantarflexion isometric strength (change-score from average of first 3 training sessions and last 3 training sessions).</description>
          <units>Newton meters</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Dorsiflexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33.7" spread="41.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Plantarflexion</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="31.5" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Active Motion Test</title>
        <description>Tracking task. Active joint position control between dorsiflexion/plantarflexion (change-score from average of first 3 training sessions and last 3 training sessions). The score is based on the amount of time that the participant is able to position the joint in a 3 deg-wide target zone presented on a video screen.</description>
        <time_frame>First 3 training sessions (week 1-2); Last 3 training sessions (week 9-10)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Test Group</title>
            <description>Group receiving AMES therapy</description>
          </group>
        </group_list>
        <measure>
          <title>Active Motion Test</title>
          <description>Tracking task. Active joint position control between dorsiflexion/plantarflexion (change-score from average of first 3 training sessions and last 3 training sessions). The score is based on the amount of time that the participant is able to position the joint in a 3 deg-wide target zone presented on a video screen.</description>
          <units>Seconds</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="2"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.8" spread="0.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year, 1 month</time_frame>
      <desc>Verbal inquiry at the beginning of each training session.</desc>
      <group_list>
        <group group_id="E1">
          <title>Test Treatment Group</title>
          <description>Device: Subjects receiving AMES treatments.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Fall</sub_title>
                <description>Loss of balance during moving</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="3"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination due to lack of funding lead to only 2 subjects treated and analyzed.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Paul J. Cordo</name_or_title>
      <organization>Oregon Health &amp; Science University</organization>
      <phone>503-418-2520</phone>
      <email>cordop@ohsu.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

